Cerus (NASDAQ:CERS) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Tuesday, ValuEngine reports.

A number of other research firms also recently weighed in on CERS. Zacks Investment Research raised Cerus from a “hold” rating to a “buy” rating and set a $6.50 price target on the stock in a research note on Monday, February 4th. BidaskClub raised Cerus from a “hold” rating to a “buy” rating in a research note on Wednesday, February 20th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Cerus presently has a consensus rating of “Hold” and a consensus target price of $8.50.

Shares of NASDAQ:CERS opened at $5.53 on Tuesday. The stock has a market capitalization of $756.74 million, a PE ratio of -12.57 and a beta of 1.38. The company has a debt-to-equity ratio of 0.85, a quick ratio of 2.50 and a current ratio of 2.83. Cerus has a 1 year low of $4.70 and a 1 year high of $8.05.

Cerus (NASDAQ:CERS) last announced its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). Cerus had a negative net margin of 90.68% and a negative return on equity of 74.31%. The business had revenue of $17.50 million during the quarter, compared to analyst estimates of $15.31 million. During the same period in the prior year, the firm earned ($0.11) earnings per share. The firm’s revenue for the quarter was up 29.0% compared to the same quarter last year. On average, equities research analysts forecast that Cerus will post -0.44 EPS for the current fiscal year.

In related news, SVP Carol Moore sold 10,886 shares of the company’s stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $6.01, for a total transaction of $65,424.86. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Richard J. Benjamin sold 9,890 shares of the company’s stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $5.96, for a total value of $58,944.40. Following the transaction, the insider now directly owns 3,000 shares in the company, valued at $17,880. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 54,867 shares of company stock worth $241,151. 7.26% of the stock is owned by company insiders.

Hedge funds have recently bought and sold shares of the stock. Two Sigma Securities LLC acquired a new position in Cerus during the 4th quarter worth approximately $55,000. Raymond James Trust N.A. bought a new stake in Cerus during the 4th quarter worth approximately $71,000. Virtu Financial LLC increased its holdings in Cerus by 16.6% during the 1st quarter. Virtu Financial LLC now owns 12,639 shares of the biotechnology company’s stock worth $79,000 after purchasing an additional 1,798 shares in the last quarter. Shufro Rose & Co. LLC increased its holdings in Cerus by 13.3% during the 4th quarter. Shufro Rose & Co. LLC now owns 17,000 shares of the biotechnology company’s stock worth $86,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Great West Life Assurance Co. Can increased its holdings in Cerus by 141.8% during the 4th quarter. Great West Life Assurance Co. Can now owns 19,824 shares of the biotechnology company’s stock worth $97,000 after purchasing an additional 11,624 shares in the last quarter. 66.37% of the stock is currently owned by institutional investors and hedge funds.

Cerus Company Profile

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

See Also: What is insider trading?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.